Synthesis of a New Zinc-Mixed Ligand Complex and Evaluation of Its Antidiabetic Properties in High Fat Diet: Low Dose Streptozotocin Induced Diabetic Rats.
- Author:
Muruganantham KOOTHAPPAN
1
;
Roshana Devi VELLAI
;
Iyyam Pillai SUBRAMANIAN
;
Sorimuthu Pillai SUBRAMANIAN
Author Information
- Publication Type:Brief Communication
- Keywords: Diabetes mellitus, type 2; Hypoglycemic agents; Metformin; Rats; Zinc
- MeSH: Administration, Oral; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, High-Fat*; Glucose; Glucose Tolerance Test; Homeostasis; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Metformin; Rats*; Streptozocin*; Zinc
- From:Diabetes & Metabolism Journal 2018;42(3):244-248
- CountryRepublic of Korea
- Language:English
- Abstract: Due to the multifactorial and multisystemic nature of diabetes mellitus, it is often treated with a combination of therapeutic agents having different mode of action. Earlier, we have synthesized several organozinc complexes and evaluated their safety and antidiabetic properties in experimental type 2 diabetes mellitus (T2DM). More recently, we have synthesized a metformin-3-hydroxyflavone complex and studied its antidiabetic efficacy in experimental rats. In the present study, a new zinc-mixed ligand (metformin-3-hydroxyflavone) was synthesized, characterized by spectral studies and its antidiabetic properties was evaluated in HFD fed—low dose streptozotocin induced T2DM in rats. The hypoglycemic efficacy of the complex was evaluated through oral glucose tolerance test, homeostasis model assessment of insulin resistance, quantitative insulin sensitivity check index and by determining the status of important biochemical parameters. Oral administration of the complex at a concentration of 10 mg/kg body weight/rat/day for 30 days significantly improved the glucose homeostasis. The complex possesses significant antidiabetic properties relatively at a less concentration than metformin-3-hydroxyflavone complex in ameliorating hyperglycemia.
